Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2020

June 2020 | 327 pages | ID: PC9672AD33CEN
Global Markets Direct

Abstracts

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor - Pipeline Review, H1 2020, provides an overview of the Peripheral Nerve Sheath Tumor (Oncology) pipeline landscape.
Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Peripheral Nerve Sheath Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 5, 4 and 1 respectively.
Peripheral Nerve Sheath Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Oncology).
• The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Aldeyra Therapeutics Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Apexian Pharmaceuticals Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by AstraZeneca Plc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BeiGene Ltd, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bexion Pharmaceuticals LLC, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BNOAT Oncology Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Calithera Biosciences Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Epizyme Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Millennium Pharmaceuticals Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Oncomatryx Biopharma SL, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Open Therapeutics LLC, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Resverlogix Corp, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sorrento Therapeutics Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, H1 2020
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Aldeyra Therapeutics Inc
Apexian Pharmaceuticals Inc
AstraZeneca Plc
BeiGene Ltd
Bexion Pharmaceuticals LLC
BNOAT Oncology Inc
Calithera Biosciences Inc
Epizyme Inc
F. Hoffmann-La Roche Ltd
Merck & Co Inc
Millennium Pharmaceuticals Inc
Novartis AG
Oncomatryx Biopharma SL
Open Therapeutics LLC
Pfizer Inc
Plexxikon Inc
Resverlogix Corp
Sorrento Therapeutics Inc
Vyriad Inc